Literature DB >> 29805618

High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer.

Yan Zhang1, Jiaxuan Zhang2, Qin Shen3, Wei Yin2, Hua Huang4, Yifei Liu4, Qingfeng Ni2.   

Abstract

Nectins are Ca2+-independent immunoglobulin-like cell adhesion molecules that belong to a family of four members that function in a number of biological cellular activities. Nectin-4 is overexpressed in several types of human cancer; however, the functional and prognostic significance of Nectin-4 in gastric cancer (GC) remains unclear. In the present study, the reverse transcription-quantitative polymerase chain reaction and tissue microarray immunohistochemical analysis were used to investigate the expression of Nectin-4 in GC as well as its function in the prognosis of patients with GC. The results indicated that mRNA and protein expression of Nectin-4 were increased in tumor tissues compared with the matched non-tumor tissues. Expression of Nectin-4 was closely associated with differentiation (P=0.004), primary tumor (P=0.001), lymph node metastasis (P<0.001) and tumor-node-metastasis (TNM) stage (P<0.001). Positive Nectin-4 expression (P=0.001) and advanced TNM stage (P<0.001) were demonstrated to be associated with overall survival time in multivariate analyses. These results suggest that Nectin-4 may serve a significant function in GC and may serve as a novel clinic pathological biomarker and therapeutic target in GC.

Entities:  

Keywords:  Nectin-4; gastric cancer; immunohistochemistry; prognosis; reverse transcription-quantitative polymerase chain reaction

Year:  2018        PMID: 29805618      PMCID: PMC5950544          DOI: 10.3892/ol.2018.8365

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.

Authors:  E Bousquet; O Calvayrac; J Mazières; I Lajoie-Mazenc; N Boubekeur; G Favre; A Pradines
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

3.  MEK/ERK regulates adherens junctions and migration through Rac1.

Authors:  Ramesh M Ray; Rajiv J Vaidya; Leonard R Johnson
Journal:  Cell Motil Cytoskeleton       Date:  2007-03

4.  Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.

Authors:  Veronica Henderson; Basil Smith; Liza J Burton; Diandra Randle; Marisha Morris; Valerie A Odero-Marah
Journal:  Cell Adh Migr       Date:  2015-07-24       Impact factor: 3.405

5.  Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer.

Authors:  Songshi Ni; Liqin Xu; Jianfei Huang; Jian Feng; Huijun Zhu; Gui Wang; Xudong Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

6.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

7.  ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility.

Authors:  Emmanuel Vial; Erik Sahai; Christopher J Marshall
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

Review 8.  The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin.

Authors:  Yoshimi Takai; Wataru Ikeda; Hisakazu Ogita; Yoshiyuki Rikitake
Journal:  Annu Rev Cell Dev Biol       Date:  2008       Impact factor: 13.827

9.  Poor survival for US Pacific Islander cancer patients: evidence from the Surveillance, Epidemiology, and End Results database: 1991 to 2004.

Authors:  William B Goggins; Grace K C Wong
Journal:  J Clin Oncol       Date:  2007-12-20       Impact factor: 44.544

10.  Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain.

Authors:  Stephanie Fabre; Nicolas Reymond; Francesca Cocchi; Laura Menotti; Patrice Dubreuil; Gabriella Campadelli-Fiume; Marc Lopez
Journal:  J Biol Chem       Date:  2002-05-14       Impact factor: 5.157

View more
  16 in total

Review 1.  The emerging role of antibody-drug conjugates in urothelial carcinoma.

Authors:  Michael Lattanzi; Jonathan E Rosenberg
Journal:  Expert Rev Anticancer Ther       Date:  2020-07-21       Impact factor: 4.512

Review 2.  The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.

Authors:  Andres Garcia-Sampedro; Gabriella Gaggia; Alexander Ney; Ismahan Mahamed; Pilar Acedo
Journal:  J Clin Med       Date:  2021-02-03       Impact factor: 4.241

Review 3.  Nectin-4: a Novel Therapeutic Target for Skin Cancers.

Authors:  Hiroki Hashimoto; Yuka Tanaka; Maho Murata; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-03-21

4.  Nectin-4 is widely expressed in head and neck squamous cell carcinoma.

Authors:  Christine Sanders; Jan-Frederic Lau; Dimo Dietrich; Sebastian Strieth; Peter Brossart; Glen Kristiansen
Journal:  Oncotarget       Date:  2022-10-20

Review 5.  Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.

Authors:  Kirollos S Hanna
Journal:  Drugs       Date:  2020-01       Impact factor: 9.546

6.  Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.

Authors:  Thomas Powles; Jonathan E Rosenberg; Guru P Sonpavde; Yohann Loriot; Ignacio Durán; Jae-Lyun Lee; Nobuaki Matsubara; Christof Vulsteke; Daniel Castellano; Chunzhang Wu; Mary Campbell; Maria Matsangou; Daniel P Petrylak
Journal:  N Engl J Med       Date:  2021-02-12       Impact factor: 91.245

7.  NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target.

Authors:  Maho Murata; Takamichi Ito; Yuka Tanaka; Yumiko Kaku-Ito; Masutaka Furue
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

8.  NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer-An Integrative Multi-Omics Approach.

Authors:  Christine Bekos; Besnik Muqaku; Sabine Dekan; Reinhard Horvat; Stephan Polterauer; Christopher Gerner; Stefanie Aust; Dietmar Pils
Journal:  Cancers (Basel)       Date:  2019-05-20       Impact factor: 6.639

9.  The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.

Authors:  Jin-Shu Pang; Zhe-Kun Li; Peng Lin; Xiao-Dong Wang; Gang Chen; Hai-Biao Yan; Sheng-Hua Li
Journal:  Oncol Rep       Date:  2019-02-14       Impact factor: 3.906

Review 10.  Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.

Authors:  Jeffrey L Wong; Jonathan E Rosenberg
Journal:  Expert Opin Biol Ther       Date:  2021-05-24       Impact factor: 5.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.